Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

@article{Sekine2004PhaseIS,
  title={Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma},
  author={Ikuo Sekine and Hiroshi Nokihara and Atsushi Horiike and Noboru Yamamoto and Hideo Kunitoh and Yuichiro Ohe and Tomohide Tamura and Tetsuro Kodama and Nagahiro George Saijo},
  journal={British Journal of Cancer},
  year={2004},
  volume={90},
  pages={1125 - 1128}
}
The recommended phase II dose of paclitaxel 180 mg m−2 given as a 3-h infusion followed by nedaplatin 100 mg m−2 in a 1-h infusion every 3–4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising response rate for lung SCC of 55%. 

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Cancer: Principles & Practice of Oncology, 6th edn Philadelphia

  • VT DeVita, S Hellman, SA Rosenberg
  • 2001
2 Excerpts

Phase I and pharmacokinetic (PK) study of (Glycolate-0, 00)-diammine platinum (II) (Nedaplatin: 254S) in elderly patients with non-small cell lung cancer (NSCLC)

  • N Yamamoto, T Tamura, T Kurata
  • Proc Am Soc Clin Oncol
  • 2000
1 Excerpt

Similar Papers

Loading similar papers…